The verdict
Our read at a glance.
Whether GHRP-2 and GHRP-6's ability to raise growth hormone supports the muscle, recovery, and anti-aging claims made for them in the gray market.
- The signal
- Human studies show GHRP-2 and GHRP-6 reliably raise growth hormone, and GHRP-2 (pralmorelin) is used as a diagnostic agent for growth-hormone deficiency in some countries. Evidence for the muscle, recovery, and anti-aging claims people make is limited, and they are not approved for those uses.
- The unknown
- Whether raising growth hormone with these peptides produces meaningful benefits beyond biomarker changes, whether the growth-hormone response fades with repeated use, and how older or diagnostic research applies to gray-market products.
- Our read
- Real growth-hormone-releasing peptides with a narrow diagnostic use, not proven muscle or anti-aging therapies. GHRP-2 and GHRP-6 do raise growth hormone, but the evidence for the claims people buy them for is thin, and the gray-market identity and safety questions are the real story.
The mechanism
How it works.
GHRP-2 and GHRP-6 are small synthetic peptides that act as ghrelin-receptor agonists. They bind the growth-hormone secretagogue receptor in the pituitary and hypothalamus and trigger the pituitary to release growth hormone in pulses, which in turn raises IGF-1 from the liver. This growth-hormone effect is well documented in humans, and GHRP-6 also strongly activates the appetite side of ghrelin signaling, so it tends to drive hunger.
Safety & regulatory boundary
The consequential part.
GHRP-2 and GHRP-6 are not approved for muscle or anti-aging use, and outside narrow diagnostic contexts they are sold as research chemicals where product identity and quality are uncertain. They raise growth hormone and can affect appetite and other systems, which is not free of risk. A jurisdiction-specific diagnostic approval for GHRP-2 does not validate muscle or anti-aging claims, and gray-market products are not the same as any approved diagnostic product.
What's next
What we're watching.
Any modern controlled trials, regulatory actions on gray-market GHRPs, and long-term safety data.
Context
Why this is discussed.
GHRP-2 and GHRP-6 are classic growth-hormone-releasing peptides widely discussed in the performance and anti-aging communities, often stacked with other GH-axis compounds.
The evidence base
12 cited references.
Indexed literature (PubMed)12
Drugs R D · Drugs R D · 2004
Bowers CY · Cell Mol Life Sci · 1998
Pombo M et al. · J Pediatr Endocrinol Metab · 1996
Onuki T et al. · J Pediatr Endocrinol Metab · 2024
Zhao X et al. · J Nanobiotechnology · 2025
Doi N et al. · Arzneimittelforschung · 2004
Suzuki S et al. · J Endocr Soc · 2022
Okano M et al. · Rapid Commun Mass Spectrom · 2010
Doan ND et al. · Org Lett · 2014
Cibrián D et al. · Clin Sci (Lond) · 2006
Laferrère B et al. · J Clin Endocrinol Metab · 2005
Bowers CY · J Clin Endocrinol Metab · 1994
Keep reading